Table 1 Patient characteristics.

From: Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data

Clinical characteristics

Total (n = 275)

Non-TEE (n = 266)

TEE (n = 9)

p-value*

Age, years

 < 70

231 (84.0%)

224 (84.2%)

7 (77.8%)

0.640

 ≥ 70

44 (16.0%)

42 (15.8%)

2 (22.2%)

 

Gender

Male

194 (70.5%)

187 (70.3%)

7 (77.8%)

1.000

Female

81 (29.5%)

79 (29.7%)

2 (22.2%)

 

BMI

 < 25

197 (71.6%)

190 (71.4%)

7 (77.8%)

1.000

 ≥ 25

78 (28.4%)

76 (28.6%)

2 (22.2%)

 

ECOG PS

0

190 (69.1%)

184 (69.2%)

6 (66.7%)

1.000

1

83 (30.2%)

80 (30.0%)

3 (33.3%)

 

2

2 (0.7%)

2 (0.8%)

0 (0.0%)

 

Smoking

Never

80 (29.1%)

79 (29.7%)

1 (11.1%)

0.455

Current or former

195 (70.9%)

187 (70.3%)

8 (88.9%)

 

Chemotherapeutic regimen

VP

148 (53.8%)

143 (53.8%)

5 (55.6%)

1.000

TC

119 (43.3%)

115 (43.2%)

4 (44.4%)

 

Others

8 (2.9%)

8 (3.0%)

0 (0.0%)

 

Adjuvant radiotherapy

No

158 (57.5%)

154 (57.9%)

4 (44.4%)

0.502

Yes

117 (42.5%)

112 (42.1%)

5 (55.6%)

 

Histology

Adenocarcinoma

188 (68.4%)

183 (68.8%)

5 (55.6%)

0.146

Squamous cell carcinoma

70 (25.5%)

68 (25.6%)

2 (22.2%)

 

Others

17 (6.2%)

15 (5.6%)

2 (22.2%)

 

Stage

IB

39 (14.2%)

39 (14.7%)

0 (0.0%)

 

IIA

12 (4.4%)

12 (4.5%)

0 (0.0%)

0.630

IIB

89 (32.4%)

84 (31.6%)

5 (55.6%)

 

IIIA

103 (37.5%)

100 ( 37.6%)

3 (33.3%)

 

IIIB

32 (11.5%)

31 (11.6%)

1 (11.1%)

 

Diabetes mellitus

No

220 (80.0%)

212 (79.7%)

8 (88.9%)

0.693

Yes

55 (20.0%)

54 (20.3%)

1 (11.1%)

 

Hypertension

No

195 (70.9%)

188 (70.7%)

7 (77.8%)

1.000

Yes

80 (29.1%)

78 (29.3%)

2 (22.2%)

 

History of vascular disease†

No

257 (93.5%)

248 (93.2%)

9 (100.0%)

1.000

Yes

18 (6.5%)

18 (6.8%)

0 (0.0%)

 

Khorana score

1

222 (80.7%)

214 (80.5%)

8 (88.9%)

 

2

50 (18.2%)

49 (18.3%)

1 (11.1%)

1.000

3

2 (0.7%)

2 (0.8%)

0 (0.0%)

 

4

1 (0.4%)

1 (0.4%)

0 (0.0%)

 

Time interval between surgery and the start of adjuvant chemotherapy

 < 45 days‡

137 (49.8%)

135 (50.8%)

2 (22.2%)

0.172

 ≥ 45 days

138 (50.2%)

131 (49.2%)

7 (77.8%)

 
  1. TEE thromboembolic event, BMI body mass index, ECOG Eastern Cooperative Oncology Group, PS performance status, VP vinorelbine/cisplatin, TC paclitaxel/carboplatin.
  2. *Fisher’s exact test.
  3. †Types of vascular disease in the patients were identified as either coronary arterial occlusive disease or cerebrovascular disease.
  4. ‡Median.
Back to article page